Related Experiment Video
Updated: Apr 4, 2026
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
[Proteomics and breast cancer: new perspectives and limitations]
1ERI-8 Inserm << signalisation des facteurs de croissance dans le cancer du sein >>, IFR-118, université des sciences et technologies de Lille, Villeneuve d'Ascq, France. hubert.hondermarck@univ-lillel.fr
Abstract:
From differential analysis for the identification of biomarkers, to functional analysis for the evidencing of new therapeutic targets, proteomics brings new comprehensive information for a better understanding of the molecular basis of oncology and new perspectives for the clinic. However the major limitation of proteomic investigations and more generally of post-genomic approaches remains the molecular and cellular complexity of biological systems. This will be illustrated with the case of breast cancer.
Insights
Proteomics offers valuable insights into cancer biology and potential new treatments by identifying biomarkers and therapeutic targets. However, the complexity of biological systems, particularly in breast cancer, remains a significant challenge for proteomic research.
Area of Science:
- Proteomics and Oncology
- Biomarker Discovery
- Therapeutic Target Identification
Background:
- Proteomics provides comprehensive molecular data for understanding cancer.
- It aids in identifying potential biomarkers and therapeutic targets.
- Challenges include the inherent complexity of biological systems.
Discussion:
- Proteomic investigations face limitations due to biological complexity.
- This complexity impacts post-genomic approaches in oncology.
- Breast cancer serves as a relevant case study for these challenges.
Key Insights:
- Differential and functional proteomics enhance cancer research.
- Understanding molecular mechanisms is crucial for clinical perspectives.
- Overcoming system complexity is key to advancing proteomics.
Outlook:
- Future research must address biological complexity for clinical translation.
- Advanced proteomic strategies are needed for oncology.
- New therapeutic avenues may emerge from overcoming these challenges.
